The association of obesity with osteoarthritis of the hand and knee in women: a twin study.
ABSTRACT To examine the association of obesity and osteoarthritis (OA) at various sites in middle aged women and to estimate the magnitude of the weight difference associated with OA.
A co-twin control study was performed within a population based twin study of women aged 48-70. OA was defined radiologically using site specific features and a standard atlas. Twin pairs discordant for OA disease traits were analyzed.
The mean weight differences (95% CI) within twin pairs discordant for different OA traits were: tibiofemoral osteophytes 3.75 (1.29, 6.21) kg; patellofemoral osteophytes 3.05 (0.96, 5.15) kg; carpometacarpal (CMC) osteophytes 3.06 (0.83, 5.28) kg. There was no significant difference in weight within twin pairs discordant for osteophytes at the distal interphalangeal (DIP) or proximal interphalangeal (PIP) joints or for joint space narrowing at all sites examined except the patellofemoral joint, 4.73 (1.61, 7.84) kg. For each kg increase in weight the increased likelihood of developing different OA traits [OR (95% CI)] was: tibiofemoral osteophytes 1.14 (1.01-1.28), patellofemoral osteophytes 1.32 (1.09-1.59), patellofemoral narrowing 1.15 (1.01-1.30), and CMC osteophytes 1.09 (1.02-1.17).
Obesity is an important risk factor for development of OA at the tibiofemoral and patellofemoral joints of the knee and CMC joints of the hands, with significant increases of 9-13% in risk of OA per kg increase in body weight. This emphasizes the potential importance of even minor weight reduction as a preventive health measure for OA.
Full-textDOI: · Available from: Flavia Cicuttini, Jul 16, 2014
- SourceAvailable from: Yoosik Yoon
[Show abstract] [Hide abstract]
- "Overweight or obesity substantially raises a patient's risk of morbidity from hypertension  , type 2 diabetes  , dyslipidemia , cardiovascular disease (CVD) , stroke , gallbladder disease , osteoarthritis , sleep apnea, respiratory problems  , and also endometrial, breast, prostate, and colon cancers . Overweight and obesity are a major public health concern not only in western countries but also in Asian countries because of its increasing prevalence and its association to morbidity and mortality  . "
ABSTRACT: We investigated the effects of herbal extracts, a mixture of Scutellariae Radix and Platycodi Radix containing the active ingredients Baicalin and Saponin (target herbal ingredient (THI)), on lowering body weight. The present study was a prospective, randomized, double-blind, and placebo-controlled trial carried out at the outpatient department of a hospital over a period of 2 months. Group 1 patients (n = 30) received THI, and group 2 patients (n = 23) received placebo three times a day before meals. Weight, waist circumference, BMI, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and glucose were measured at baseline and again at the 2nd month. For safety evaluation, various hematological and biochemical parameters were assessed. Values of mean change of weight in the THI-treated group were -1.16 ± 1.41 kg and in the placebo-treated group were -0.24 ± 1.70 kg, respectively. The difference in mean change of weight in the THI-treated group compared with that in the placebo-treated group was statistically significant (P < 0.05). The incidence of subjective and objective adverse drug reactions was insignificant (P > 0.05). THI was statistically significant in its effectiveness on the weight loss.Evidence-based Complementary and Alternative Medicine 10/2013; 2013:758273. DOI:10.1155/2013/758273 · 1.88 Impact Factor
[Show abstract] [Hide abstract]
- "Most of the increased risk for orthopaedic diseases, such as osteoarthritis (OA), can be explained by the 'mechanical overload' effect of obesity. However, the development of OA in non-weightbearing joints, such as the hand, is also associated with increasing BMI in humans (Cicuttini et al., 1996), and symptomatic improvement of OA is more closely related to loss of body fat than overall weight loss (Toda et al., 1998). Therefore, other pathogenetic, likely metabolic, mechanisms may contribute to the link between OA and obesity. "
ABSTRACT: Obesity is characterised by an expansion of white adipose tissue mass that can lead to adverse health effects, such as decreased longevity, diabetes mellitus, orthopaedic and respiratory disease and neoplasia. Once thought a passive fuel depot, adipose tissue is now recognised as an active endocrine organ that communicates with the brain and peripheral tissues by secreting a wide range of hormones and protein factors, collectively termed adipokines. Examples include leptin, adiponectin, cytokines (tumour necrosis factor-alpha, interleukin-6), chemokines, acute phase proteins, haemostatic and haemodynamic factors and neurotrophins. Adipokines can influence various body systems, and perturbation of normal endocrine function is thought central to the development of many associated conditions. This review focuses on the medical consequences of obesity in companion animals, assesses the endocrine function of adipose tissue in disease pathogenesis, and highlights the potential role of adipokines as biomarkers of obesity-associated disease.The Veterinary Journal 07/2010; 185(1):4-9. DOI:10.1016/j.tvjl.2010.04.004 · 2.17 Impact Factor
[Show abstract] [Hide abstract]
- "Obesity is a significant risk factor for both the development and progression of tibio-femoral knee OA (both symptomatic and radiographic) [Hart et al. 1999; Cicuttini et al. 1997, 1996; Felson et al. 1997, 1992, 1988; Bagge et al. 1991]. An association, though modest, has also been demonstrated between obesity and OA at other sites such as the hip, hand and patellofemoral joint, suggesting that both mechanical and metabolic factors may be responsible for the link between OA and obesity. "
ABSTRACT: Osteoarthritis (OA) is the most common form of arthritis and the leading cause of chronic disability among older people. The burden of the disease is expected to rise with an aging population and the increasing prevalence of obesity. Despite this, there is as yet no cure for OA. However, in recent years, a number of potential therapeutic advances have been made, in part due to improved understanding of the underlying pathophysiology. This review provides the current evidence for symptomatic management of OA including nonpharmacological, pharmacological and surgical approaches. The current state of evidence for disease-modifying therapy in OA is also reviewed.Therapeutic advances in musculoskeletal disease 02/2010; 2(1):17-28. DOI:10.1177/1759720X09359889